In this issue:
Intensified therapy of ALL in adults
Obinutuzumab or rituximab for previously untreated follicular lymphoma
Ibrutinib for R/R follicular lymphoma
Obinutuzumab + bendamustine in rituximab-refractory NHL
Brentuximab vedotin + gemcitabine in R/R Hodgkin lymphoma
Bendamustine + obinutuzumab + venetoclax in CLL
Rituximab and transformation risk in follicular lymphoma
Prolonged ATO and ATRA for relapsed APL
Ponatinib in Ph+ leukaemia
Risk-adapted treatment of APL
Please login below to download this issue (PDF)